nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2022-5-109-116nnp-1900Research ArticleEXPERT CONSENSUSКОНСЕНСУС ЭКСПЕРТОВApplication of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research SocietyПрименение новой биологической патогенетической терапии мигрени в клинической практике: консенсус экспертов Российского общества по изучению головной болиhttps://orcid.org/0000-0002-7142-3719СергеевА. В.SergeevA. V.

119991, Москва, ул. Трубецкая, 8, стр. 2

8, Trubetskaya St., Build. 2, Moscow 119991

sergeev.neuro@gmail.comhttps://orcid.org/0000-0002-3833-532XТабееваГ. Р.TabeevaG. R.

119991, Москва, ул. Трубецкая, 8, стр. 2

8, Trubetskaya St., Build. 2, Moscow 119991

https://orcid.org/0000-0001-9978-4180ФилатоваЕ. Г.FilatovaE. G.

119991, Москва, ул. Трубецкая, 8, стр. 2

8, Trubetskaya St., Build. 2, Moscow 119991

https://orcid.org/0000-0001-6437-232XАмелинА. В.AmelinA. V.

197022, Санкт-Петербург, ул. Льва Толстого, 6-8

6-8; Lev Tolstoy St., St. Petersburg 197022

https://orcid.org/0000-0002-1177-6424АхмадееваЛ. Р.AkhmadeevaL. R.

450008, Уфа, ул. Ленина, 3

3, Lenin St., Ufa 450008

https://orcid.org/0000-0003-2463-7113ЛебедеваЕ. Р.LebedevaE. R.

620028, Екатеринбург, ул. Репина, 3;

620144, Екатеринбург, ул. Фурманова, 67

3, Repin St., Yekaterinburg 620028;

67, Furmanov St., Yekaterinburg 620144

https://orcid.org/0000-0002-1570-5009ОсиповаВ. В.OsipovaV. V.

115419, Москва, ул. Донская, 43

43, Donskaya St., Moscow 115419

https://orcid.org/0000-0002-3713-4884АзимоваЮ. Э.AzimovaYu. E.

121467, Москва, ул. Молодогвардейская, 2, корп. 1;

125315, Москва, ул. Балтийская, 8

2, Molodogvardeiskaya St., Build. 1, Moscow 121467

8, Baltiyskaya St., Moscow 125315

https://orcid.org/0000-0001-9600-5540ЛатышеваН. В.LatyshevaN. V.

119991, Москва, ул. Трубецкая, 8, стр. 2

8, Trubetskaya St., Build. 2, Moscow 119991

https://orcid.org/0000-0003-2865-077XДоронинаО. Б.DoroninaO. B.

630091, Новосибирск, Красный проспект, 52

52, Krasnyi Prospect, Novosibirsk 630091

https://orcid.org/0000-0002-1279-9548СкоробогатыхК. В.SkorobogatykhK. V.

121467, Москва, ул. Молодогвардейская, 2, корп. 1

2, Molodogvardeiskaya St., Build. 1, Moscow 121467

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian FederationФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава РоссииРоссияAcad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRussian FederationФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава РоссииРоссияBashkir State Medical University, Ministry of Health of RussiaRussian FederationФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России; Международный центр лечения головной боли «Европа-Азия»РоссияUral State Medical University, Ministry of Health of Russia; International Headache Treatment Center “Europe-Asia”Russian FederationГБУЗ «Научно-практический психоневрологический центр им. З.П. Соловьева Департамента здравоохранения города Москвы»РоссияZ.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare DepartmentRussian FederationООО «Университетская клиника головной боли»; ФГБНУ «Научно-исследовательский институт общей патологии и патофизиологии»РоссияOOO “University Headache Clinic”; Research Institute of General Pathology and PathophysiologyRussian FederationФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава РоссииРоссияNovosibirsk State Medical University, Ministry of Health of RussiaRussian FederationООО «Университетская клиника головной боли»РоссияOOO “University Headache Clinic”Russian Federation202225102022145109116Copyright © Sergeev A.V., Tabeeva G.R., Filatova E.G., Amelin A.V., Akhmadeeva L.R., Lebedeva E.R., Osipova V.V., Azimova Y.E., Latysheva N.V., Doronina O.B., Skorobogatykh K.V., 20222022Сергеев А.В., Табеева Г.Р., Филатова Е.Г., Амелин А.В., Ахмадеева Л.Р., Лебедева Е.Р., Осипова В.В., Азимова Ю.Э., Латышева Н.В., Доронина О.Б., Скоробогатых К.В.Sergeev A.V., Tabeeva G.R., Filatova E.G., Amelin A.V., Akhmadeeva L.R., Lebedeva E.R., Osipova V.V., Azimova Y.E., Latysheva N.V., Doronina O.B., Skorobogatykh K.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1900

This consensus reviewed the main current issues of clinical application and integration into everyday practice of a new targeted preventive therapy for migraine using monoclonal antibodies (mAbs) to the calcitonin gene related peptide (CGRP) ligand or receptor. These recommendations are based on current scientific and clinical studies and an analysis of the results of several years of clinical use. The main purpose of the consensus is to assist practitioners in prescribing effective prophylactic treatment of migraine using anti-CGRP mAbs and to improve care for patients with various forms of the disease. 

В настоящем консенсусе рассмотрены основные текущие вопросы клинического применения и интеграции в повседневную практику новой таргетной профилактической терапии мигрени с использованием моноклональных антител (мАТ) к лиганду или рецептору кальцитонин-ген-родственного пептида (CGRP). Данные рекомендации разработаны на основании данных текущих современных научных и клинических исследований и анализа результатов нескольких лет клинического использования этих препаратов. Основная цель консенсуса – помочь практикующим специалистам в назначении эффективного профилактического лечения мигрени с использованием мАТ к CGRP и улучшение помощи пациентам с различными формами заболевания. 

мигреньмоноклональные антителакальцитонин-ген-родственный пептидконсенсусmigrainemonoclonal antibodiescalcitonin gene-related peptideconsensusReferencesОсипова ВВ, Табеева ГР. Первичные головные боли: диагностика, клиника, терапия: Практическое руководство. Москва: Медицинское информационное агентство; 2014. 336 с.Osipova VV, Tabeeva GR. Pervichnyye golovnyye boli: diagnostika, klinika, terapiya: Prakticheskoye rukovodstvo [Primary headaches: diagnosis, clinic, therapy: A practical guide]. Moscow: Medical Information Agency; 2014. 336 p. (In Russ.).Lipton RB, Bigal ME, Diamond M, et al; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30;68(5):343-9. doi: 10.1212/01.wnl.0000252808.97649.21Lipton RB, Bigal ME, Diamond M, et al; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30;68(5):343-9. doi: 10.1212/01.wnl.0000252808.97649.21Steiner TJ, Stovner LJ, Jensen R, et al; Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137. doi: 10.1186/s10194-020-01208-0Steiner TJ, Stovner LJ, Jensen R, et al; Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137. doi: 10.1186/s10194-020-01208-0Ashina M, Katsarava Z, Do TP, et al. Migraine: epidemiology and systems of care. Lancet. 2021 Apr 17;397(10283):1485-95. doi: 10.1016/S0140-6736(20)32160-7Ashina M, Katsarava Z, Do TP, et al. Migraine: epidemiology and systems of care. Lancet. 2021 Apr 17;397(10283):1485-95. doi: 10.1016/S0140-6736(20)32160-7Raval AD, Shah A. National trends in direct health care expenditures among US adults with migraine: 2004 to 2013. J Pain. 2017 Jan;18(1):96-107. doi: 10.1016/j.jpain.2016.10.005. Epub 2016 Oct 24.Raval AD, Shah A. National trends in direct health care expenditures among US adults with migraine: 2004 to 2013. J Pain. 2017 Jan;18(1):96-107. doi: 10.1016/j.jpain.2016.10.005. Epub 2016 Oct 24.Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009 Apr;49(4):498-508. doi: 10.1111/j.1526- 4610.2009.01369.x. Epub 2009 Feb 25.Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009 Apr;49(4):498-508. doi: 10.1111/j.1526- 4610.2009.01369.x. Epub 2009 Feb 25.The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202Азимова ЮЭ, Амелин АВ, Алферова ВВ и др. Клинические рекомендации «Мигрень». Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(13):4-36. doi: 10.17116/jnevro20221220134Azimova YuE, Amelin AV, Alferova VV, et al. Clinical guidelines “Migraine”. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2022;122(1-3):4-36. doi: 10.17116/jnevro20221220134 (In Russ.).Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39. doi: 10.1111/head.14153. Epub 2021 Jun 23.Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39. doi: 10.1111/head.14153. Epub 2021 Jun 23.Табеева ГР, Осипова ВВ, Филатова ЕГ и др. Диагностика и лечение лекарственно-индуцированной головной боли: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):4-13. doi: 10.14412/2074-2711-2022-1-4-13Tabeeva GR, Osipova VV, Filatova EG, et al. Evaluation and treatment of medication-overuse headache: Russian experts’ guidelines. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):4-13. doi: 10.14412/2074-2711-2022-1-4-13 (In Russ.).Alasad YW, Asha MZ. Monoclonal antibodies as a preventive therapy for migraine: a meta-analysis. Clin Neurol Neurosurg. 2020 Aug;195:105900. doi: 10.1016/j.clineuro.2020.105900. Epub 2020 May 11.Alasad YW, Asha MZ. Monoclonal antibodies as a preventive therapy for migraine: a meta-analysis. Clin Neurol Neurosurg. 2020 Aug;195:105900. doi: 10.1016/j.clineuro.2020.105900. Epub 2020 May 11.Инструкция по медицинскому применению лекарственного препарата Аджови. Доступно по ссылке: https://grls.rosminzdrav.ru/ (дата обращения 02.08.2022).Instructions for the medical use of the drug Ajovy. Available from: https://grls.rosminzdrav.ru/ (accessed 08/02/2022) (In Russ.).Инструкция по медицинскому применению лекарственного препарата Иринэкс. Доступно по ссылке: https://grls.rosminzdrav.ru/ (дата обращения 02.08.2022).Instructions for the medical use of the drug Irinex. Available from: https://grls.rosminzdrav.ru/ (accessed 08/02/2022) (In Russ.).Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019 Sep 21;394(10203):1030-40. doi: 10.1016/S0140-6736(19)31946-4. Epub 2019 Aug 16. Erratum in: Lancet. 2019 Oct 29Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019 Sep 21;394(10203):1030-40. doi: 10.1016/S0140-6736(19)31946-4. Epub 2019 Aug 16. Erratum in: Lancet. 2019 Oct 29Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017 Nov 30;377(22):2113-22. doi: 10.1056/NEJMoa1709038.Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017 Nov 30;377(22):2113-22. doi: 10.1056/NEJMoa1709038.Levin M, Silberstein SD, Gilbert R, et al. Basic Considerations for the Use of Monoclonal Antibodies in Migraine. Headache. 2018 Nov;58(10):1689-96. doi: 10.1111/head.13439. Epub 2018 Nov 13.Levin M, Silberstein SD, Gilbert R, et al. Basic Considerations for the Use of Monoclonal Antibodies in Migraine. Headache. 2018 Nov;58(10):1689-96. doi: 10.1111/head.13439. Epub 2018 Nov 13.Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020 Nov 3;95(18):e2487- e2499. doi: 10.1212/WNL.0000000000010600 Epub 2020 Sep 10.Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020 Nov 3;95(18):e2487- e2499. doi: 10.1212/WNL.0000000000010600 Epub 2020 Sep 10.Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 Sep 26;55(6):754-62. doi: 10.1212/wnl.55.6.754Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 Sep 26;55(6):754-62. doi: 10.1212/wnl.55.6.754American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019 Jan;59(1):1-18. doi: 10.1111/head.13456. Epub 2018 Dec 10.American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019 Jan;59(1):1-18. doi: 10.1111/head.13456. Epub 2018 Dec 10.Silberstein SD, Cohen JM, Seminerio MJ, et al. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain. 2020 Sep 21;21(1):114. doi: 10.1186/s10194-020-01173-8Silberstein SD, Cohen JM, Seminerio MJ, et al. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain. 2020 Sep 21;21(1):114. doi: 10.1186/s10194-020-01173-8Cainazzo MM, Baraldi C, Ferrari A, et al. Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. Neurol Sci. 2021 Oct;42(10):4193-202. doi: 10.1007/s10072-021-05105-5. Epub 2021 Feb 5.Cainazzo MM, Baraldi C, Ferrari A, et al. Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. Neurol Sci. 2021 Oct;42(10):4193-202. doi: 10.1007/s10072-021-05105-5. Epub 2021 Feb 5.Tepper SJ, Diener HC, Ashina M, et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019 May 14;92(20):e2309-e2320. doi: 10.1212/WNL.0000000000007497. Epub 2019 Apr 17.Tepper SJ, Diener HC, Ashina M, et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019 May 14;92(20):e2309-e2320. doi: 10.1212/WNL.0000000000007497. Epub 2019 Apr 17.Silberstein SD, Dodick D, Freitag F, et al. Pharmacological approaches to managing migraine and associated comorbidities clinical considerations for monotherapy versus polytherapy. Headache. 2007 Apr;47(4):585-99. doi: 10.1111/j.1526-4610.2007.00760.xSilberstein SD, Dodick D, Freitag F, et al. Pharmacological approaches to managing migraine and associated comorbidities clinical considerations for monotherapy versus polytherapy. Headache. 2007 Apr;47(4):585-99. doi: 10.1111/j.1526-4610.2007.00760.xYuan H, Baggaley S, Ozudogru S, Digre K. CGRP antibodies as adjunctive prophylactic therapy for prolonging the therapeutic effect of onabotulinumtoxinA injections among chronic migraine patients (P09). Headache. 2020;59(Suppl. 1):1-208.Yuan H, Baggaley S, Ozudogru S, Digre K. CGRP antibodies as adjunctive prophylactic therapy for prolonging the therapeutic effect of onabotulinumtoxinA injections among chronic migraine patients (P09). Headache. 2020;59(Suppl. 1):1-208.Pellesi L, Do TP, Ashina H, et al. Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache. 2020 Jun;60(6):1056-65. doi: 10.1111/head.13843. Epub 2020 May 21.Pellesi L, Do TP, Ashina H, et al. Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache. 2020 Jun;60(6):1056-65. doi: 10.1111/head.13843. Epub 2020 May 21.Cohen F, Yuan H, Dent K, et al. Realworld Effectiveness of Add-on Fremanezumab in Patients Receiving OnabotulinumtoxinA for Chronic Migraine in a US Tertiary Headache Center. Poster presented at the Migraine Trust International Symposium (MTIS); 8–11 September 2022; London, England, UK; 2022.Cohen F, Yuan H, Dent K, et al. Realworld Effectiveness of Add-on Fremanezumab in Patients Receiving OnabotulinumtoxinA for Chronic Migraine in a US Tertiary Headache Center. Poster presented at the Migraine Trust International Symposium (MTIS); 8–11 September 2022; London, England, UK; 2022.Caronna E, Gallardo VJ, Alpuente A, et al. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain. 2021 Oct 7;22(1):120. doi: 10.1186/s10194-021- 01328-1Caronna E, Gallardo VJ, Alpuente A, et al. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain. 2021 Oct 7;22(1):120. doi: 10.1186/s10194-021- 01328-1Robblee J, Starling AJ. SEEDS for success: lifestyle management in migraine. Cleve Clin J Med. 2019 Nov;86(11):741-9. doi: 10.3949/ccjm.86a.19009Robblee J, Starling AJ. SEEDS for success: lifestyle management in migraine. Cleve Clin J Med. 2019 Nov;86(11):741-9. doi: 10.3949/ccjm.86a.19009Coeytaux RR, Kaufman JS, Chao R, et al. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol. 2006 Apr;59(4):374-80. doi: 10.1016/j.jclinepi.2005.05.010Coeytaux RR, Kaufman JS, Chao R, et al. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol. 2006 Apr;59(4):374-80. doi: 10.1016/j.jclinepi.2005.05.010Tassorelli C, Diener H-C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018 Apr;38(5):815-32. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.Tassorelli C, Diener H-C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018 Apr;38(5):815-32. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine. Cephalalgia. 2011 Feb;31(3):357-67. doi: 10.1177/0333102410379890. Epub 2010 Sep 6.Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine. Cephalalgia. 2011 Feb;31(3):357-67. doi: 10.1177/0333102410379890. Epub 2010 Sep 6.Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20-8. doi: 10.1212/wnl.56.suppl_1.s20.Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20-8. doi: 10.1212/wnl.56.suppl_1.s20.Tepper SJ, Ashina M, Reuter U, et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia. 2020 May;40(6):543-53. doi: 10.1177/0333102420912726. Epub 2020 Mar 26Tepper SJ, Ashina M, Reuter U, et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia. 2020 May;40(6):543-53. doi: 10.1177/0333102420912726. Epub 2020 Mar 26Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018 Nov 9;18(1):188. doi: 10.1186/s12883-018-1193-2Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018 Nov 9;18(1):188. doi: 10.1186/s12883-018-1193-2Kanaan S, Hettie G, Loder E, Burch R. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia. 2020 Nov;40(13):1511-22. doi: 10.1177/0333102420946725. Epub 2020 Aug 13.Kanaan S, Hettie G, Loder E, Burch R. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia. 2020 Nov;40(13):1511-22. doi: 10.1177/0333102420946725. Epub 2020 Aug 13.Ashina M, Kudrow D, Reuter U, et al. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebocontrolled trials with long-term extensions. Cephalalgia. 2019 Dec;39(14):1798-808. doi: 10.1177/0333102419888222. Epub 2019 Nov 10.Ashina M, Kudrow D, Reuter U, et al. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebocontrolled trials with long-term extensions. Cephalalgia. 2019 Dec;39(14):1798-808. doi: 10.1177/0333102419888222. Epub 2019 Nov 10.Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain. 2022 Jun 11;23(1):67. doi: 10.1186/s10194-022-01431-xSacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain. 2022 Jun 11;23(1):67. doi: 10.1186/s10194-022-01431-xTerhart M, Mecklenburg J, Neeb L, et al. Deterioration of headache impact and healthrelated quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J Headache Pain. 2021 Dec 31;22(1):158. doi: 10.1186/s10194-021-01368-7Terhart M, Mecklenburg J, Neeb L, et al. Deterioration of headache impact and healthrelated quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J Headache Pain. 2021 Dec 31;22(1):158. doi: 10.1186/s10194-021-01368-7

The authors declare that there are no conflicts of interest present.